Trials / Withdrawn
WithdrawnNCT02031211
TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial
Etanercept for the Treatment of Chronic Regional Pain Syndrome
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- Female
- Age
- 10 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
Studying the effects of Etanercept (an anti-Tumor Necrosis Factor alpha) on early Chronic Regional Pain Syndrome (CRPS). Our hypothesis is that Etanercept will improve patient symptoms if given in early CRPS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etanercept | The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously. |
| DRUG | Placebo | The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously. |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2016-10-01
- Completion
- 2016-10-01
- First posted
- 2014-01-09
- Last updated
- 2016-10-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02031211. Inclusion in this directory is not an endorsement.